Why Is Intuitive Surgical (ISRG) Up 7.1% Since Last Earnings Report?

Intuitive Surgical topped Q3 2025 estimates with adjusted EPS of $2.40 versus $1.99 and revenue of $2.51 billion (+23% YoY), driven by 19% da Vinci procedure volume growth, higher system placements (427 shipped, including 240 da Vinci 5 systems) and broad strength across instruments, systems and services. Adjusted operating income rose 29% and operating margin widened to 38.9% despite a 110bp decline in gross margin to 68%; cash and investments fell to $8.43 billion from $9.53 billion. Analysts have nudged estimates up (consensus +5% in the past month) and the stock is ~7% higher since the print, but mixed VGM scores (Growth C, Momentum/Value D) and margin dynamics imply further upside will depend on continued execution and future estimate revisions rather than an immediate re-rating.

Analysis

Intuitive Surgical reported third-quarter 2025 adjusted EPS of $2.40 versus the Zacks consensus of $1.99 (beat by 20.6%) and GAAP EPS of $1.95 (up 25% YoY), while revenue was $2.51 billion, up 23% YoY and 3.9% ahead of estimates. Revenue strength was broad-based: Instruments & Accessories totaled $1.52 billion (+20.1%) supported by 19% procedure volume growth and strong Ion (+52%) and SP (+91%) growth, Systems revenue was $590.4 million (+32.7%) with 427 shipments and 240 da Vinci 5 placements, and Services reached $395.9 million (+20.4%).

Adjusted gross profit rose to $1.70 billion (+21%) but gross margin compressed ~110 basis points to 68%; higher SG&A (+12.3%) and R&D (+15.2%) were offset by operating leverage, lifting adjusted operating income to $975.9 million (+29.2%) and operating margin to 38.9% (+190 bps). Cash and investments declined to $8.43 billion from $9.53 billion the prior quarter, creating a near-term liquidity/usage datapoint investors should track.

Market response has been moderately positive (shares ~+7.1% since the print) and consensus estimates have ticked up ~5% in the last month, but aggregate VGM score of D and a Zacks Rank #3 (Hold) imply the stock needs sustained execution—continued procedure volume growth, da Vinci 5 adoption and gross-margin stabilization—to justify a stronger re-rating.

Key Decisions for Investors

• Maintain a modest exposure or add incrementally on pullbacks given 23% revenue growth and accelerating da Vinci 5 placements, but avoid initiating full-size positions until margin trends and cash usage are clearer
• Monitor quarterly guidance and KPIs closely—specifically system placements, procedure volume/mix and gross-margin trajectory—and reduce exposure if margin compression persists or consensus estimate revisions reverse
• Use continued upward revisions and stable/improving operating margins as a catalyst to increase conviction; consider hedging or trimming if sentiment remains mixed despite execution